Semester project in Biomedical Engineering – A new GPVI inhibitor for anti-platelet therapy: from assay development to lead compounds


Platelets play an important role on thrombosis and anti-platelet therapies even though efficient, they have the limitation of haemorrhagic side effects. GPVI deficiency has been identified in patients who presented, at the most, significant reduction on collagen-induced thrombus formation, but a slight tendency to mild bleeding, indicating that GPVI inhibition might be able to reduce thrombus formation without causing severe bleeding. In this project, we aim to find molecules able to inhibit the GPVI receptor. Thus, small compounds selected by virtual screening will be tested using a platelet-based assay optimized and validated in our laboratory.

Responsible contact: Augusto Martins Lima


Platelet aggregate